PhaseBio Pharmaceuticals Profit Margin

The latest profit margin for PHAS is 3402.93% as of June 2022. That compares with -1054.49% in the prior-year period — up 422.7% year over year. That is above the Healthcare sector average of 9.71%. Investors often review this figure alongside PhaseBio Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PHAS's profit margin moved from -1054.49% to 3402.93% — a 422.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PhaseBio Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, PHAS currently prints 3402.93% for profit margin, while the sector average sits near 9.71%. That is roughly 34960.0% above the sector mean. Large gaps often invite a closer look at PhaseBio Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively PhaseBio Pharmaceuticals converts resources into returns. At 3402.93%, PHAS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1054.49% in the prior-year period — up 422.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PHAS's profit margin (3402.93%), review year-over-year change from -1054.49%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.